Central Park. Image of The Mall area in Central Park, New York City, USA at autumn.

Janssen Pharms., Inc. v. Tolmar, Inc. – Invega Sustenna® (Paliperidone Palmitate)

Start
Case Name: Janssen Pharms., Inc. v. Tolmar, Inc., Civ. No. 21-1784-WCB, 2024 WL 2972832 (D. Del. June 13, 2024) (Bryson, J.) – Drug Product and Patent(s)-in-Suit: Invega Sustenna® (paliperidone palmitate); U.S. Patent No. 9,439,906 (“the ’906 patent”)….
By: Robins Kaplan LLP
Previous Story

Governor Pritzker Signs BIPA Amendment, Nick Palmieri

Next Story

Apple’s instructions to its new Siri GenAI offering illustrate the GenAI challenge